These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23301710)

  • 21. The long battle over payment for oncology services in the office setting.
    Bailes JS; Coleman TS
    J Oncol Pract; 2014 Jan; 10(1):1-4. PubMed ID: 24443726
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessing the pricing and benefits of oncology products: an update.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):335-342. PubMed ID: 33950772
    [No Abstract]   [Full Text] [Related]  

  • 23. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 24. [Carbon footprint and cancer: Time for green oncology?].
    Guillon S; Nguyen Ba E; Oufkir N; Hequet D; Rouzier R
    Bull Cancer; 2020 May; 107(5):612-613. PubMed ID: 32245606
    [No Abstract]   [Full Text] [Related]  

  • 25. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 26. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reforming the payment system for medical oncology.
    Bach PB
    JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
    [No Abstract]   [Full Text] [Related]  

  • 28. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 29. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 30. Medicare cost containment strategy targets several oncology drugs.
    Twombly R
    J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
    [No Abstract]   [Full Text] [Related]  

  • 31. Should the American Society of Clinical Oncology Ask for Peer Review Before Publishing Its Advocacy Research?
    Bach PB
    J Clin Oncol; 2016 Dec; 34(36):4447-4448. PubMed ID: 27998217
    [No Abstract]   [Full Text] [Related]  

  • 32. Managing oncology agents: an HMO's perspective.
    Jaramillo R
    Manag Care; 2007 Mar; 16(3 Suppl 4):16-8; discussion 18-9. PubMed ID: 18575218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel approaches to delivering value in oncology drugs.
    Miller S
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
    [No Abstract]   [Full Text] [Related]  

  • 36. Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
    Green AK; Ohn JA; Bach PB
    J Clin Oncol; 2020 Feb; 38(4):372-379. PubMed ID: 31804856
    [No Abstract]   [Full Text] [Related]  

  • 37. Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
    Lotvin AM; Shrank WH; Singh SC; Falit BP; Brennan TA
    Health Aff (Millwood); 2014 Oct; 33(10):1736-44. PubMed ID: 25288417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Science and society: Fifty years later--the 2014 presidential address.
    Hudis CA
    J Clin Oncol; 2015 Jan; 33(2):127-32. PubMed ID: 25452454
    [No Abstract]   [Full Text] [Related]  

  • 39. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can treatment costs be tamed?
    Malakoff D
    Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.